News
Microdosing Research News
Latest — updated August 10, 2026
New evidence worth logging:
Dose-response confirmed at the top: 7.2 mg data
STEP UP quantified the trade: greater weight loss at 7.2 mg with more dose reductions for adverse events (18.5% vs 12.4% at 2.4 mg) and a dysesthesia signal (~1 in 5) — the cleanest evidence yet that effect and tolerability both ride the dose curve.
Monitored category — items publish only when newsworthy and sourced.
The research-news category tracks new GLP-1 microdosing and dose-response studies: trial registrations, publications, and their findings and limitations. We link the primary record — a DOI, PMID, or ClinicalTrials.gov identifier — and never report a result from a press release alone.
What we watch in this category
- New dose-response and reduced-dose trials for semaglutide and tirzepatide
- Maintenance and withdrawal study publications
- Real-world cohorts on compounded products
- Registrations that have not yet reported
Primary sources monitored
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.